Longitudinal end point optimization to provide assessments of relevant drugs

The University of Rochester received a $2.93 million cooperative agreement award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) for the period of August 1, 2022 through July 31, 2026. The award, titled "LONGITUDINAL END POINT OPTIMIZATION TO PROVIDE ASSESSMENTS OF RELEVANT DRUGS," will support the University's work to transform healthcare for service members and the public through innovative biomedical research investigating medical solutions for battlefield use. A subaward of $150,000 was provided to The Metis Foundation to support the project's "LONGITUDINAL ENDPOINT OPTIMIZATION TO PROVIDE ASSESSMENTS OF RELEVANT DRUGS" objectives. The funding will allow the University and Foundation to conduct research aimed at optimizing longitudinal clinical trial endpoints to efficiently assess relevant drugs over the four-year period of performance in Rochester, New York.